WALTHAM, Mass., Nov. 8, 2018 /PRNewswire/ — MicroMedicine, Inc., a life sciences technology company, recently announced the appointment of Dr. Marcela Maus to its Scientific Advisory Board. Dr. Maus is an oncologist and also the Director of Cellular Immunotherapy at the Massachusetts General Hospital (MGH) Cancer Center. She is a member of the Center for Cancer Immunology and the Department of Medicine at MGH, as well as an assistant professor at Harvard Medical School.  Dr. Maus’ laboratory focuses on creating next-generation CAR T-cells (chimeric antigen receptor T-cells).   Dr. Maus trained with pioneer Carl June, MD at the University of Pennsylvania and is a leader in the field of cancer immunology with particular expertise in T-cell immunotherapies. 

Dr. Marcela Maus

“I am very excited to join MicroMedicine’s Advisory Board and offer insights that may help to further develop novel cell isolation technologies. The fields of cell therapy and regenerative medicine are in urgent need of a bioengineering-driven approach to the manufacturing process, starting with efficient and less manipulative methods for cell handling and extraction. The development of gentler and more precise technology shows great promise to assist researchers and therapy developers in meeting their goals,” says Dr. Maus.

Co-founder and CEO of MicroMedicine, Dr. Ravi Kapur commented, “Dr. Maus’s expertise and guidance will accelerate the advancement of our microfluidic platform technology to address the key challenges in cell therapy manufacturing and regenerative medicine. We are thrilled to have her on our Advisory Board and consider it further validation of our focus and application in this space.” 

About MicroMedicine, Inc.

MicroMedicine, Inc., is a life sciences company that develops high-volume microfluidic technologies for target cell isolation from biological fluids for the purposes of research and clinical applications. Founded at Massachusetts General Hospital in 2015 by prominent physicians and researchers, MicroMedicine is committed to transforming research, clinical diagnostics, and cell therapy with novel innovations.  The patented microfluidic platform can be utilized for multiple applications, including cell isolation, cell concentration, and fluid exchange.  The company recently re-located to the heart of Boston’s life sciences ecosystem in Waltham, Massachusetts.

For more information about MicroMedicine, Inc., please call 617-744-1918 or visit micromedicine.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/micromedicine-announces-new-advisory-board-member-dr-marcela-maus-300747081.html

SOURCE MicroMedicine, Inc.